FREE Account Opening + No Clearing Fees
Loading...

Gland Pharma IPO vs RailTel IPO

Comparision between Gland Pharma IPO and RailTel IPO.

IPO Details

Gland Pharma IPO is a Mainline Book Built Issue IPO proposed to list at BSE, NSE while RailTel IPO is a Mainline Book Built Issue proposed to list at BSE, NSE.

Issue Size and Price

The total issue size of Gland Pharma IPO is up to ₹6,479.55 Cr whereas the issue size of the RailTel IPO is up to ₹819.24 Cr. The final issue price of Gland Pharma IPO is ₹1,500.00 per share and of RailTel IPO is ₹94.00 per share.

  Gland Pharma IPO RailTel IPO
Face Value ₹1 per share ₹10 per share
Issue Price (Lower) ₹1,490.00 per share ₹93.00 per share
Issue Price (Upper) ₹1,500.00 per share ₹94.00 per share
Issue Price (Final) ₹1,500.00 per share ₹94.00 per share
Discount (Retail)
Discount (Employee)
Market Lot Size 10 shares 155 shares
Fresh Issue Size 83,33,333 shares
Fresh Issue Size (Amount) up to ₹1,250.00 Cr
OFS Issue Size 3,48,63,635 shares 8,71,53,369 shares
OFS Issue Size (Amount) up to ₹5,229.55 Cr up to ₹819.24 Cr
Issue Size Total 4,31,96,968 shares 8,71,53,369 shares
Issue Size Total (Amount) up to ₹6,479.55 Cr up to ₹819.24 Cr

IPO Timetable

Gland Pharma IPO opens on Nov 09, 2020, while RailTel IPO opens on Feb 16, 2021. The closing date of Gland Pharma IPO and RailTel IPO is Nov 11, 2020, and Feb 18, 2021, respectively.

  Gland Pharma IPO RailTel IPO
Anchor Bid Date
Issue Open Nov 09, 2020 Feb 16, 2021
Issue Close Nov 11, 2020 Feb 18, 2021
Basis Of Allotment (Tentative) Nov 17, 2020 Feb 23, 2021
Initiation of Refunds (Tentative) Nov 18, 2020 Feb 24, 2021
Credit of Share (Tentative) Nov 19, 2020 Feb 24, 2021
Listing date (Tentative) Nov 20, 2020 Feb 26, 2021
Anchor Lockin End date 1 Dec 17, 2020 Mar 25, 2021
Anchor Lockin End date 2 Feb 15, 2021 May 24, 2021

Financials

Gland Pharma IPO P/E ratio is , as compared to RailTel IPO P/E ratio of .

  Gland Pharma IPO RailTel IPO
Financial
Summary of financial Information (Restated Consolidated)
Particulars For the year/period ended (Rs in million)
30-June-20 31-Mar-20 31-Mar-19 31-Mar-18
Total Assets 46,912.65 40,860.39 35,235.49 29,294.68
Total Revenue 9,162.89 27,724.08 21,297.67 16,716.82
Profit After Tax 3,135.90 7,728.58 4,518.56 3,210.51
Summary of financial Information (Restated Consolidated)
Particulars For the year/period ended (Rs in million)
30-Sep-20 31-Mar-20 31-Mar-19 31-Mar-18
Total Assets 24,821.50 23,981 22,276.75 23,228.79
Total Revenue 5,537.84 11,660.05 10,382.66 10,212.18
Profit After Tax 455.84 1,410.66 1,353.56 1,340.06
Promoter Shareholding (Pre-Issue) 74% 100%
Promoter Shareholding (Post-Issue) 58% 72.84%
P/E Ratio
Market Cap
ROE
ROCE
Debt/Equity
EPS
RoNW

Shares Offered

In the Gland Pharma IPO retail investors (RII) are offered 1,51,18,939 shares while in RailTel IPO retail investors are offered 1,51,18,939 shares. Qualified institutional buyers (QIB) are offered 86,39,394 shares in Gland Pharma IPO and 1,73,69,237 shares in RailTel IPO.

  Gland Pharma IPO RailTel IPO
Anchor Investor Reserveration
Market Maker Reserveration
QIB 86,39,394 shares 1,73,69,237 shares
NII 64,79,546 shares 1,29,98,006 shares
RII 1,51,18,939 shares 3,03,28,680 shares
Employee 0 shares 5,00,000 shares
Others
Total 3,02,37,879 shares 6,11,95,923 shares

Bids Received (Subscription)

Gland Pharma IPO subscribed 2.06x in total, whereas RailTel IPO subscribed 42.39x.

  Gland Pharma IPO RailTel IPO
QIB (times) 6.40x 65.14x
NII (times) 0.51x 73.25x
Big NII (times)
Small NII (times)
RII (times) 0.24x 16.78x
Employee (times) 3.35x
Other (times)
Total (times) 2.06x 42.39x

Comments

Add a public comment...